| pubmed-article:11163404 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11163404 | lifeskim:mentions | umls-concept:C1155065 | lld:lifeskim |
| pubmed-article:11163404 | lifeskim:mentions | umls-concept:C0042210 | lld:lifeskim |
| pubmed-article:11163404 | lifeskim:mentions | umls-concept:C0441471 | lld:lifeskim |
| pubmed-article:11163404 | lifeskim:mentions | umls-concept:C0184511 | lld:lifeskim |
| pubmed-article:11163404 | lifeskim:mentions | umls-concept:C0599894 | lld:lifeskim |
| pubmed-article:11163404 | lifeskim:mentions | umls-concept:C2827421 | lld:lifeskim |
| pubmed-article:11163404 | pubmed:issue | 9 | lld:pubmed |
| pubmed-article:11163404 | pubmed:dateCreated | 2001-2-22 | lld:pubmed |
| pubmed-article:11163404 | pubmed:abstractText | Live, attenuated vaccines currently offer the best protection against virulent pathogens. Recent advances in Immunology and Molecular Biology provide an opportunity to design vaccines that will be more effective and safer than existing ones. Immunologists are rapidly developing the capacity to identify and construct the minimal immunogenic units from pathogens. The molecular signals required to fully activate antigen presenting cells (APCs) and responder T cells are becoming apparent. Improved vaccine delivery systems are being designed which will mimic the actions of pathogens in vivo. These vaccines will incorporate protective epitopes fused to immunoregulatory cytokines in chimeric proteins. They will be encapsulated in formulations which allow for the slow release of these chimeric proteins thereby inducing the memory T cells required for long-lived immunity. These vaccine formulations will target receptors present on the most active APCs. Here we discuss how these advances will allow us to rationally construct "virtual pathogens" which will provide improved protection against new and old microbial foes. | lld:pubmed |
| pubmed-article:11163404 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11163404 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11163404 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11163404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11163404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11163404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11163404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11163404 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11163404 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11163404 | pubmed:month | Jun | lld:pubmed |
| pubmed-article:11163404 | pubmed:issn | 0161-5890 | lld:pubmed |
| pubmed-article:11163404 | pubmed:author | pubmed-author:BairdM AMA | lld:pubmed |
| pubmed-article:11163404 | pubmed:author | pubmed-author:YoungS LSL | lld:pubmed |
| pubmed-article:11163404 | pubmed:author | pubmed-author:WalesJJ | lld:pubmed |
| pubmed-article:11163404 | pubmed:author | pubmed-author:FaulknerLL | lld:pubmed |
| pubmed-article:11163404 | pubmed:author | pubmed-author:LockhartE AEA | lld:pubmed |
| pubmed-article:11163404 | pubmed:author | pubmed-author:BuchanG SGS | lld:pubmed |
| pubmed-article:11163404 | pubmed:author | pubmed-author:SlobbeLL | lld:pubmed |
| pubmed-article:11163404 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11163404 | pubmed:volume | 37 | lld:pubmed |
| pubmed-article:11163404 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11163404 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11163404 | pubmed:pagination | 545-52 | lld:pubmed |
| pubmed-article:11163404 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:meshHeading | pubmed-meshheading:11163404... | lld:pubmed |
| pubmed-article:11163404 | pubmed:year | 2000 | lld:pubmed |
| pubmed-article:11163404 | pubmed:articleTitle | Targeting early events in T cell activation to construct improved vaccines. | lld:pubmed |
| pubmed-article:11163404 | pubmed:affiliation | Department of Microbiology, University of Otago School of Medical Sciences, P.O. Box 56, Dunedin, New Zealand. glen.buchan@stonebow.otago.ac.nz | lld:pubmed |
| pubmed-article:11163404 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11163404 | pubmed:publicationType | Review | lld:pubmed |
| pubmed-article:11163404 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
